To accelerate discovery, scientists from ATCC and the Broad Institute collaborated to engineer a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.
Researchers engineered a panel of drug-resistant NSCLC models using CRISPR gene editing and gene overexpression techniques.
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants. The study, published in Cancer ...
As many as 1 in 4 cancers are driven by mutations in the SWI/SNF chromatin-remodeling complex, which controls access to DNA.
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Rezatapopt is a first-in-class oral therapy designed to target the TP53 Y220C mutation. This mutation affects the p53 protein ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
On April 15, Onconic Therapeutics announced that it would release research results on its next-generation anticancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results